CHMP backs J&J's teclistamab for earlier-line relapsed/refractory myeloma

CHMP moves teclistamab toward second line

On 17 September 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending TECVAYLI (teclistamab) for relapsed/refractory multiple myeloma in patients who have had at least one prior therapy, an earlier-line indication that expands on teclistamab's current later-line EU label ^[1]. The signal was reported by J&J's own release and corroborated the same day by OncLive, whose account specifies teclistamab monotherapy in the earlier-line setting ^[1][2].

Teclistamab is a BCMA×CD3 bispecific T-cell engager, marketed by Janssen Biotech under BLA761291 ^[7]. Teclistamab is already established in Europe: the European Commission granted full approval of TECVAYLI plus daratumumab for relapsed/refractory myeloma on 21 August 2026 ^[6], and the US FDA cleared TECVAYLI plus DARZALEX FASPRO as early as second line on 5 March 2026 ^[5]. The current US label still frames teclistamab as combination therapy with daratumumab/hyaluronidase for patients with at least one prior line that included a proteasome inhibitor and an immunomodulatory agent, or as monotherapy only after four prior lines ^[4]. A CHMP recommendation after one prior therapy therefore continues teclistamab's steady march from a last-resort option toward the earlier lines where patient volumes and competitive stakes are far larger.

Why it matters

Earlier-line access is where a BCMA bispecific franchise is won or lost. Each line the label moves up multiplies the eligible population and the number of prescribing decisions where teclistamab sits on the menu before a competitor is even considered. A CHMP positive opinion is a recommendation, not a marketing authorisation: the European Commission typically issues its binding decision within roughly two months of the opinion, which places a likely EU authorisation in the November 2026 window, Prognyx's estimate from the standard post-opinion clock, not a date J&J has published.

J&J is not defending a single asset. Its Q2 2026 results flagged TALVEY (talquetamab, a GPRC5D bispecific) plus DARZALEX FASPRO in earlier-line myeloma as a pipeline highlight and listed TECVAYLI among the oncology drivers of Innovative Medicine growth ^[10]. The company is running a Phase 3 trial of talquetamab-plus-teclistamab combinations against standard EPd/PVd regimens (NCT06208150, n=838, active but no longer recruiting, primary completion listed 1 April 2026, no results yet posted) ^[12], and, tellingly, is testing whether its own investigational agent JNJ-79635322 can beat teclistamab head-to-head in a 700-patient Phase 3 (NCT07518186, recruiting) ^[11]. J&J is engineering teclistamab's eventual successor while pushing teclistamab into earlier lines.

What to watch next

• The European Commission's binding decision on this indication, expected within roughly two months of the opinion (Prognyx estimate: around November 2026).
• Readout of the talquetamab-plus-teclistamab Phase 3 (NCT06208150), whose primary completion is listed as 1 April 2026 with no results yet posted ^[12].
• The JNJ-79635322-versus-teclistamab head-to-head (NCT07518186), which will define whether J&J cannibalises its own franchise ^[11].

Investigator and NCI trials continue to widen teclistamab's footprint, daratumumab combinations (NCT06948084, recruiting) ^[13], iberdomide combinations (NCT06465316, recruiting) ^[14], and new tumor types including plasmablastic lymphoma (NCT07332507) ^[15] and Waldenström's macroglobulinemia (NCT07791498, not yet open) ^[16]. Nature Medicine has published a randomized Phase 2 of teclistamab versus lenalidomide-dexamethasone in high-risk smoldering myeloma ^[17], signalling ambitions well upstream of the relapsed setting.

The now-what

For a competing BCMA program, three options are on the table. First, contest the second-line data directly, the earlier-line battle will be decided on depth and durability of response, not on being present in the class. Second, differentiate on administration or safety, since teclistamab carries a known post-marketing adverse-event profile now under real-world FAERS scrutiny ^[18]. Third, target the settings J&J has not yet locked, the smoldering and non-myeloma indications where the label has not moved.

What Prognyx could not verify

Two other BCMA-directed bispecific antibodies already have US approvals: elranatamab (Pfizer's Elrexfio) received FDA accelerated approval on 14 August 2023, and linvoseltamab (Regeneron's Lynozyfic) on 2 July 2025 ^[21]. Prognyx covered AbbVie's etentamig Phase 3 data on 4 September 2026. This briefing does not compare their efficacy with teclistamab's. The CHMP opinion is recorded on the EMA's page for Tecvayli ^[20] and was reported in J&J's release and same-day OncLive coverage; OncLive characterises the recommendation as teclistamab monotherapy, while a separately dated CancerNetwork headline frames it as a combination and, dated June 2026, could not be reconciled here against the 17 September opinion and may reflect an earlier, distinct opinion.

Verdict: Moderate, near-term threat to any BCMA bispecific competing for second-line EU share, window to act closes with the EC decision expected around November 2026.